‘Too good to be true’: A Chinese study on timing cancer therapy is retracted
Sign up now: Get insights on Asia's fast-moving developments
Those who received intravenous infusions in the morning had their cancer kept at bay for twice as long as those who got it in the afternoon, according to the study.
PHOTO: UNSPLASH
Rebecca Robbins
BEIJING - In early 2026, a medical journal article caught the attention of cancer patients and doctors worldwide because of its extraordinary conclusion. Simply changing the time of day that immunotherapy was administered appeared to produce a stunning benefit for lung cancer patients.
Those who received intravenous infusions in the morning had their cancer kept at bay for twice as long as those who got it in the afternoon, according to the results from a clinical trial in China and published in the journal Nature Medicine in February.